An International Randomised Trial of Celecoxib versus Celecoxib plus Difluoromethylornithine in Patients with Familial Adenomatous Polyposis | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
scientific articles

An International Randomised Trial of Celecoxib versus Celecoxib plus Difluoromethylornithine in Patients with Familial Adenomatous Polyposis

key information

source: Gut Journal

year: 2015

authors: Patrick M. Lynch, Carol A. Burke, Robin Phillips, Jeffrey S. Morris, Xuemei Wang, Jun Liu, Rebecca Slack, Sherri Patterson

summary/abstract:

BACKGROUND AND AIM : Although Non-steroidal anti-inflammatory drugs reduce colorectal adenoma burden in familial adenomatous polyposis (FAP), the utility of combining chemopreventive agents in FAP is not known. We conducted a randomised trial of celecoxib (CXB) versus CXB+diflouromethylornithine (DFMO) to determine the synergistic effect, if any.

METHODS : The primary endpoint was % change in adenoma count in a defined field. Secondary endpoints were adenoma burden (weighted by adenoma diameter) and video review of entire colon/rectal segments. Adverse event (AEs) were monitored by National Cancer Institution toxicity criteria.

RESULTS : 112 subjects were randomised: 60 men and 52 women at a mean age of 38 years. For the 89 patients who had landmark-matched polyp counts available at baseline and 6 months, the mean % change in adenoma count over the 6 months of trial was -13.0% for CXB+DFMO and -1.0% for CXB (p=0.69). Mean % change in adenoma burden was -40% (CXB+DFMO) vs -27% (CXB) (p=0.13). Video-based global polyp change was -0.80 for CXB+DFMO vs -0.33 for CXB (p=0.03). Fatigue was the only significant AE, worse on the CXB arm (p=0.02).

CONCLUSIONS : CXB combined with DFMO yielded moderate synergy according to a video-based global assessment. No significant difference in adenoma count, the primary endpoint, was seen between the two study arms. No evidence of DFMO-related ototoxicity was seen. There were no adverse cardiovascular outcomes in either trial arm and no significant increase in AEs in the CXB+DFMO arm of the trial. Differences in outcomes between primary and secondary endpoints may relate to sensitivity of the endpoint measures themselves.

TRIAL REGISTRATION NUMBER : ClinicalTrials.gov number N01-CN95040.

organization: The University of Texas M.D. Anderson Cancer Center, Cleveland Clinic, St. Mark's Hospital, Mayo Clinic, Rambam Medical Center, Hvidore Hospital, The National Cancer Institute

DOI: 10.1136/gutjnl-2014-307235

read more full text source

expertly curated content related to this topic

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close